PTCTPTC Therapeutics, Inc.
Is the business good?
The checks split: margins widening, but profits without cash flow.
Reports an operating profit but operating cash flow is negative, a red flag. Conversion is worsening vs a year ago.
Operating margin has widened over the past few years, the business is getting more profitable per dollar of sales.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.
How good a business is PTCT?
PTC Therapeutics, Inc. keeps 12% of every revenue dollar as operating profit, against −82% for the median Biotechnology name.
Operating margin · Biotechnology median −82% · 12 months to Q2 2026
- Cash conversion
- −0.31×
Cash conversion · 1.04× a year ago · the operating profit has not turned into cash yet
- Share count, year on year
- +18%
Share count, year on year · shareholders own a smaller slice than a year ago
- R&D as % of revenue
- 43%
R&D as % of revenue
| Year | Operating margin |
|---|---|
| FY2020 | −113% |
| FY2021 | −70% |
| FY2022 | −64% |
| FY2023 | −47% |
| FY2024 | −38% |
| FY2025 | 50% |
Details›
- Operating margin12 months to Q2 2026
- 12%
- Net margin12 months to Q2 2026
- −3.8%
- Free cash flow margin
- −3.9%
- R&D as % of revenue
- 43%
- Revenue, trailing twelve months
- $1.01B
- Free cash flow, trailing twelve months
- −$40M
- Net income, trailing twelve months
- −$38M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.